Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cellectis S.A. ADR (NQ: CLLS )

2.035 +0.045 (+2.26%)
Streaming Delayed Price Updated: 3:57 PM EDT, Mar 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,651
Open 2.040
Bid (Size) 2.020 (10)
Ask (Size) 2.050 (1)
Prev. Close 1.990
Today's Range 2.020 - 2.060
52wk Range 1.770 - 5.040
Shares Outstanding 45,484,310
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting
From Cellectis Inc.
Via Globe NewsWire
Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
From Cellectis Inc.
Via Globe NewsWire

Performance

YTD
-10.35%
-10.35%
1 Month
-6.65%
-6.65%
3 Month
+8.24%
+8.24%
6 Month
-14.14%
-14.14%
1 Year
-52.34%
-52.34%

More News

Read More
Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update
From Cellectis Inc.
Via Globe NewsWire
Earnings Scheduled For March 8, 2023
Via Benzinga
A Preview Of Cellectis's Earnings
Via Benzinga
Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023
From Cellectis Inc.
Via Globe NewsWire
There's a Lot of Upside For Emerging Gene-Editing Companies
Via MarketBeat
Cellectis Announces Closing of Global Offering and Exercise of Underwriters’ Option to Purchase Additional Shares
From Cellectis Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Cellectis Supplements the Announcement of the Pricing of Follow-On Offering with Allocation of Share Capital Information
From Cellectis Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Cellectis Announces Pricing of Follow-On Offering
From Cellectis Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Cellectis Announces Launch of Follow-On Offering
From Cellectis Inc.
Via Globe NewsWire
7 CRISPR Stocks With the Best Long-Term Potential
Via InvestorPlace
Cellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics
From Cellectis Inc.
Via Globe NewsWire
Why Is Calyxt (CLXT) Stock Up 140% Today?
Via InvestorPlace
Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement
From Cellectis Inc.
Via Globe NewsWire
5 Most Expensive Health Care Stocks You Should Worry About
Via Benzinga
Why Tesla Shares Are Trading Lower; Here Are 32 Stocks Moving Premarket
Via Benzinga
Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Mayflower Bioventures Launches its First Spin-Out, Primera Therapeutics, in Strategic Collaboration with Cellectis to Develop a Gene Editing Platform to Treat Mitochondrial Diseases
From Cellectis Inc.
Via Globe NewsWire
Cellectis secures a €40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities
From Cellectis Inc.
Via Globe NewsWire
Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL
From Cellectis Inc.
Via Globe NewsWire
Crispr Stock In 2023: Will Down-In-The-Dumps Shares Sparkle Again In 2023?
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.